Cross-talk of membrane lipids and Alzheimer-related proteins

Molecular Neurodegeneration

Gerhild van Echten-Deckert²  Jochen Walter¹ 

[1] EURON–European Graduate School of Neuroscience, Bonn, Germany;Life and Medical Sciences (LIMES), Membrane Biology and Lipid Biochemistry Unit at the Kekulé-Institute, University of Bonn, Gerhard-Domagk-Str. 1, 53121, Bonn, Germany

关键词: Lysosomal storage disorders;    Beta-amyloid;    Tau;    Cholesterol;    Gangliosides;    Sphingolipids;    Alzheimer’s disease;   

Others  :  862098
DOI  :  10.1186/1750-1326-8-34

 received in 2013-07-01, accepted in 2013-09-25,  发布年份 2013

【 摘 要 】

Alzheimer’s disease (AD) is neuropathologically characterized by the combined occurrence of extracellular β-amyloid plaques and intracellular neurofibrillary tangles in the brain. While plaques contain aggregated forms of the amyloid β-peptide (Aβ), tangles are formed by fibrillar forms of the microtubule associated protein tau. All mutations identified so far to cause familial forms of early onset AD (FAD) are localized close to or within the Aβ domain of the amyloid precursor protein (APP) or in the presenilin proteins that are essential components of a protease complex involved in the generation of Aβ. Mutations in the tau gene are not associated with FAD, but can cause other forms of dementia. The genetics of FAD together with biochemical and cell biological data, led to the formulation of the amyloid hypothesis, stating that accumulation and aggregation of Aβ is the primary event in the pathogenesis of AD, while tau might mediate its toxicity and neurodegeneration.

The generation of Aβ involves sequential proteolytic cleavages of the amyloid precursor protein (APP) by enzymes called β-and γ-secretases. Notably, APP itself as well as the secretases are integral membrane proteins. Thus, it is very likely that membrane lipids are involved in the regulation of subcellular transport, activity, and metabolism of AD related proteins.

Indeed, several studies indicate that membrane lipids, including cholesterol and sphingolipids (SLs) affect Aβ generation and aggregation. Interestingly, APP and other AD associated proteins, including β-and γ-secretases can, in turn, influence lipid metabolic pathways. Here, we review the close connection of cellular lipid metabolism and AD associated proteins and discuss potential mechanisms that could contribute to initiation and progression of AD.

【 授权许可】

   
2013 Walter and van Echten-Deckert; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Selkoe DJ: Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
• [2]Perrin RJ, Fagan AM, Holtzman DM: Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 2009, 461:916-922.
• [3]Spires-Jones TL, Stoothoff WH, De Calignon A, Jones PB, Hyman BT: Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 2009, 32:150-159.
• [4]Tanzi RE, Bertram L: Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
• [5]St George-Hyslop PH, Petit A: Molecular biology and genetics of Alzheimer’s disease. C R Biol 2005, 328:119-130.
• [6]Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St George-Hyslop P: The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 2003, 302:822-826.
• [7]Guerreiro RJ, Gustafson DR, Hardy J: The genetic architecture of Alzheimer’s disease: beyond APP, PSENs and APOE. Neurobiol Aging 2012, 33:437-456.
• [8]Van Echten-Deckert G, Walter J: Sphingolipids: critical players in Alzheimer’s disease. Prog Lipid Res 2012, 51:378-393.
• [9]Levine B, Kroemer G: Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
• [10]Cohen E, Dillin A: The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat Rev Neurosci 2008, 9:759-767.
• [11]Gleichmann M, Chow VW, Mattson MP: Homeostatic disinhibition in the aging brain and Alzheimer’s disease. J Alzheimers Dis 2011, 24:15-24.
• [12]Bishop NA, Lu T, Yankner BA: Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
• [13]Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer’s disease. Annu Rev Neurosci 1996, 19:53-77.
• [14]Bertram L, Lill CM, Tanzi RE: The genetics of Alzheimer disease: back to the future. Neuron 2010, 68:270-281.
• [15]Kim J, Basak JM, Holtzman DM: The role of apolipoprotein E in Alzheimer’s disease. Neuron 2009, 63:287-303.
• [16]Dietschy JM: Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 2009, 390:287-293.
• [17]Walter J: Gamma-Secretase, apolipoprotein E and Cellular cholesterol metabolism. Curr Alzheimer Res 2012, 9:189-199.
• [18]Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM: ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci U S A 2013, 110:E1807-E1816.
• [19]Nixon RA, Yang DS, Lee JH: Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 2008, 4:590-599.
• [20]Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K: Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 1989, 57:115-126.
• [21]Walter J, Schindzielorz A, Hartung B, Haass C: Phosphorylation of the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and 2. J Biol Chem 2000, 275:23523-23529.
• [22]Iwatsubo T: The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 2004, 14:379-383.
• [23]Steiner H, Fluhrer R, Haass C: Intramembrane proteolysis by gamma-secretase. J Biol Chem 2008, 283:29627-29631.
• [24]Spasic D, Annaert W: Building gamma-secretase: the bits and pieces. J Cell Sci 2008, 121:413-420.
• [25]Selkoe DJ, Wolfe MS: Presenilin: running with scissors in the membrane. Cell 2007, 131:215-221.
• [26]De Strooper B, Annaert W: Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol 2010, 26:235-260.
• [27]Thinakaran G, Koo EH: Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008, 283:29615-29619.
• [28]Kandalepas PC, Vassar R: Identification and biology of beta-secretase. J Neurochem 2012, 120(Suppl 1):55-61.
• [29]Weber S, Saftig P: Ectodomain shedding and ADAMs in development. Development 2012, 139:3693-3709.
• [30]Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992, 357:500-503.
• [31]Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small DH: Proteasome-mediated degradation of the C-terminus of the Alzheimer’s disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. J Neurosci Res 2003, 74:378-385.
• [32]Tamboli IY, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews PM, Saftig P, Sandhoff K, Walter J: Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J Neurosci 2011, 31:1837-1849.
• [33]Tamboli IY, Tien NT, Walter J: Sphingolipid storage impairs autophagic clearance of Alzheimer-associated proteins. Autophagy 2011, 7:645-646.
• [34]Agholme L, Hallbeck M, Benedikz E, Marcusson J, Kagedal K: Amyloid-beta secretion, generation, and lysosomal sequestration in response to proteasome inhibition: involvement of autophagy. J Alzheimers Dis 2012, 31:343-358.
• [35]Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN: Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009, 14:469-486.
• [36]Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA: Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid beta-peptide elimination from the brain. J Neurochem 2010, 115:1077-1089.
• [37]Saido T, Leissring MA: Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med 2012, 2:a006379.
• [38]Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ: Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? J Neurochem 2012, 120(Suppl 1):167-185.
• [39]Dietschy JM, Turley SD: Cholesterol metabolism in the brain. Curr Opin Lipidol 2001, 12:105-112.
• [40]Van Echten-Deckert G, Herget T: Sphingolipid metabolism in neural cells. Biochim Biophys Acta 2006, 1758:1978-1994.
• [41]Lütjohann D, Meichsner S, Pettersson H: Lipids in Alzheimer’s disease and their potential for therapy. Clin Lipidol 2012, 7:65-78.
• [42]He X, Huang Y, Li B, Gong CX, Schuchman EH: Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging 2010, 31:398-408.
• [43]Haughey NJ, Bandaru VV, Bae M, Mattson MP: Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim Biophys Acta 1801, 2010:878-886.
• [44]Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR: Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res 1998, 23:81-88.
• [45]Kosicek M, Hecimovic S: Phospholipids and Alzheimer’s disease: alterations, mechanisms and potential biomarkers. Int J Mol Sci 2013, 14:1310-1322.
• [46]Ehehalt R, Keller P, Haass C, Thiele C, Simons K: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003, 160:113-123.
• [47]Hartmann T, Kuchenbecker J, Grimm MO: Alzheimer’s disease: the lipid connection. J Neurochem 2007, 103(Suppl 1):159-170.
• [48]Costantini C, Kolasani RM, Puglielli L: Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer’s disease: just hypotheses or molecular pathways to be identified? Alzheimers Dement 2005, 1:43-50.
• [49]Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS: A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med 1998, 4:730-734.
• [50]Simons M, Keller P, Dichgans J, Schulz JB: Cholesterol and Alzheimer’s disease: is there a link? Neurology 2001, 57:1089-1093.
• [51]Hur JY, Welander H, Behbahani H, Aoki M, Franberg J, Winblad B, Frykman S, Tjernberg LO: Active gamma-secretase is localized to detergent-resistant membranes in human brain. Febs J 2008, 275:1174-1187.
• [52]Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE: Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 2002, 9:11-23.
• [53]Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998, 95:6460-6464.
• [54]Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG: Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004, 167:953-960.
• [55]Ledesma MD, Dotti CG: Amyloid excess in Alzheimer’s disease: what is cholesterol to be blamed for? FEBS Lett 2006, 580:5525-5532.
• [56]Rushworth JV, Hooper NM: Lipid rafts: linking alzheimer’s amyloid-beta production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis 2010, 2011:603052.
• [57]Vetrivel KS, Thinakaran G: Membrane rafts in Alzheimer’s disease beta-amyloid production. Biochim Biophys Acta 1801, 2010:860-867.
• [58]Di Paolo G, Kim TW: Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci 2011, 12:284-296.
• [59]Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G: Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem 2005, 280:25892-25900.
• [60]Cordy JM, Hooper NM, Turner AJ: The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 2006, 23:111-122.
• [61]Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR: The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012, 336:1168-1171.
• [62]Jung JI, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, Golde TE, Felsenstein KM: Steroids as gamma-secretase modulators. Faseb J 2013, 27:3775-3785.
• [63]Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ: Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2003, 100:11735-11740.
• [64]Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM: Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 2001, 3:905-912.
• [65]Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM: The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 2004, 44:227-238.
• [66]Ohm TG, Meske V: Cholesterol, statins and tau. Acta Neurol Scand Suppl 2006, 185:93-101.
• [67]Burns M, Duff K: Cholesterol in Alzheimer’s disease and tauopathy. Ann N Y Acad Sci 2002, 977:367-375.
• [68]Love S, Bridges LR, Case CP: Neurofibrillary tangles in Niemann-Pick disease type C. Brain 1995, 118:119-129.
• [69]Distl R, Treiber-Held S, Albert F, Meske V, Harzer K, Ohm TG: Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J Pathol 2003, 200:104-111.
• [70]Jin LW, Shie FS, Maezawa I, Vincent I, Bird T: Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 2004, 164:975-985.
• [71]Nixon RA: Niemann-Pick Type C disease and Alzheimer’s disease: the APP-endosome connection fattens up. Am J Pathol 2004, 164:757-761.
• [72]Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K: Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci 2003, 23:5645-5649.
• [73]Sawamura N, Gong JS, Chang TY, Yanagisawa K, Michikawa M: Promotion of tau phosphorylation by MAP kinase Erk1/2 is accompanied by reduced cholesterol level in detergent-insoluble membrane fraction in Niemann-Pick C1-deficient cells. J Neurochem 2003, 84:1086-1096.
• [74]Bu B, Li J, Davies P, Vincent I: Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 2002, 22:6515-6525.
• [75]Bhat NR, Thirumangalakudi L: Increased tau phosphorylation and impaired brain insulin/igf signaling in mice fed a high fat/high cholesterol diet. J Alzheimers Dis 2013, 36:781-789.
• [76]Glockner F, Meske V, Lutjohann D, Ohm TG: Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 2011, 70:292-301.
• [77]Pacheco CD, Elrick MJ, Lieberman AP: Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum Mol Genet 2009, 18:956-965.
• [78]Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S: Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2005, 2:e18.
• [79]Meske V, Albert F, Richter D, Schwarze J, Ohm TG: Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer’s disease. Eur J Neurosci 2003, 17:93-102.
• [80]Hamano T, Yen SH, Gendron T, Ko LW, Kuriyama M: Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging 2012, 33:2306-2320.
• [81]Li L, Zhang W, Cheng S, Cao D, Parent M: Isoprenoids and related pharmacological interventions: potential application in Alzheimer’s disease. Mol Neurobiol 2012, 46:64-77.
• [82]Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM: Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam study. J Neurol Neurosurg Psychiatry 2009, 80:13-17.
• [83]Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease: II: review of human trials and recommendations. Arch Neurol 2011, 68:1385-1392.
• [84]Wolozin B: Cholesterol, statins and dementia. Curr Opin Lipidol 2004, 15:667-672.
• [85]Hooff GP, Wood WG, Muller WE, Eckert GP: Isoprenoids, small GTPases and Alzheimer’s disease. Biochim Biophys Acta 1801, 2010:896-905.
• [86]Cole SL, Vassar R: Isoprenoids and Alzheimer’s disease: a complex relationship. Neurobiol Dis 2006, 22:209-222.
• [87]Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, Tolksdorf K, Heneka MT, Lutjohann D, Wunderlich P, Walter J: Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J Biol Chem 2010, 285:37405-37414.
• [88]Glebov K, Walter J: Statins in unconventional secretion of insulin-degrading enzyme and degradation of the amyloid-beta peptide. Neurodegener Dis 2011, 10:309-312.
• [89]Simons K, Gerl MJ: Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 2010, 11:688-699.
• [90]Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9:139-150.
• [91]Hannun YA, Obeid LM: Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995, 20:73-77.
• [92]Martinez TN, Chen X, Bandyopadhyay S, Merrill AH, Tansey MG: Ceramide sphingolipid signaling mediates tumor necrosis factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Mol Neurodegener 2012, 7:45. BioMed Central Full Text
• [93]Mencarelli C, Martinez-Martinez P: Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci 2012, 70:181-203.
• [94]Puglielli L, Ellis BC, Saunders AJ, Kovacs DM: Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 2003, 278:19777-19783.
• [95]Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J: Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem 2005, 280:28110-28117.
• [96]Li H, Kim WS, Guillemin GJ, Hill AF, Evin G, Garner B: Modulation of amyloid precursor protein processing by synthetic ceramide analogues. Biochim Biophys Acta 1801, 2010:887-895.
• [97]Sawamura N, Ko M, Yu W, Zou K, Hanada K, Suzuki T, Gong JS, Yanagisawa K, Michikawa M: Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J Biol Chem 2004, 279:11984-11991.
• [98]Zha Q, Ruan Y, Hartmann T, Beyreuther K, Zhang D: GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry 2004, 9:946-952.
• [99]Xie H, Johnson GV: Ceramide selectively decreases tau levels in differentiated PC12 cells through modulation of calpain I. J Neurochem 1997, 69:1020-1030.
• [100]Wang LJ, Colella R, Yorke G, Roisen FJ: The ganglioside GM1 enhances microtubule networks and changes the morphology of Neuro-2a cells in vitro by altering the distribution of MAP2. Exp Neurol 1996, 139:1-11.
• [101]Ferreira A, Busciglio J, Landa C, Caceres A: Ganglioside-enhanced neurite growth: evidence for a selective induction of high-molecular-weight MAP-2. J Neurosci 1990, 10:293-302.
• [102]Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM: Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J Biol Chem 2010, 285:37415-37426.
• [103]Pacheco CD, Kunkel R, Lieberman AP: Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum Mol Genet 2007, 16:1495-1503.
• [104]Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, Jackson Roberts L, Mathews PM II, Matsuoka Y, Ariga T, Yu RK, Thompson R, McDonald MP: Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol Aging 2009, 30:1777-1791.
• [105]Oikawa N, Yamaguchi H, Ogino K, Taki T, Yuyama K, Yamamoto N, Shin RW, Furukawa K, Yanagisawa K: Gangliosides determine the amyloid pathology of Alzheimer’s disease. Neuroreport 2009, 20:1043-1046.
• [106]Svennerholm L: Chromatographic separation of human brain gangliosides. J Neurochem 1963, 10:613-623.
• [107]Takasugi N, Sasaki T, Suzuki K, Osawa S, Isshiki H, Hori Y, Shimada N, Higo T, Yokoshima S, Fukuyama T, Lee VM, Trojanowski JQ, Tomita T, Iwatsubo T: BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci 2011, 31:6850-6857.
• [108]Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K: Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005, 280:36815-36823.
• [109]Hagen N, Hans M, Hartmann D, Swandulla D, Van Echten-Deckert G: Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. Cell Death Differ 2011, 18:1356-1365.
• [110]Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ: Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem 2008, 283:22529-22540.
• [111]Holmes O, Paturi S, Ye W, Wolfe MS, Selkoe DJ: Effects of membrane lipids on the activity and processivity of purified gamma-secretase. Biochemistry 2012, 51:3565-3575.
• [112]Zhang H, Ding J, Tian W, Wang L, Huang L, Ruan Y, Lu T, Sha Y, Zhang D: Ganglioside GM1 binding the N-terminus of amyloid precursor protein. Neurobiol Aging 2009, 30:1245-1253.
• [113]Yanagisawa K, Odaka A, Suzuki N, Ihara Y: GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer’s disease. Nat Med 1995, 1:1062-1066.
• [114]Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C, Yanagisawa K: Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem 1999, 274:15110-15114.
• [115]Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K: Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001, 276:24985-24990.
• [116]Matsuzaki K, Kato K, Yanagisawa K: Abeta polymerization through interaction with membrane gangliosides. Biochim Biophys Acta 1801, 2010:868-877.
• [117]Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K: A seed for Alzheimer amyloid in the brain. J Neurosci 2004, 24:4894-4902.
• [118]Yamamoto N, Igbabvoa U, Shimada Y, Ohno-Iwashita Y, Kobayashi M, Wood WG, Fujita SC, Yanagisawa K: Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett 2004, 569:135-139.
• [119]Yamamoto N, Matsubara T, Sato T, Yanagisawa K: Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim Biophys Acta 2008, 1778:2717-2726.
• [120]Kimura N, Yanagisawa K: Endosomal accumulation of GM1 ganglioside-bound amyloid beta-protein in neurons of aged monkey brains. Neuroreport 2007, 18:1669-1673.
• [121]Grimm MO, Zinser EG, Grosgen S, Hundsdorfer B, Rothhaar TL, Burg VK, Kaestner L, Bayer TA, Lipp P, Muller U, Grimm HS, Hartmann T: Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer’s disease pathology with ganglioside metabolism. PLoS One 2012, 7:e34095.
• [122]Fukami K, Inanobe S, Kanemaru K, Nakamura Y: Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance. Prog Lipid Res 2010, 49:429-437.
• [123]Di Paolo G, De Camilli P: Phosphoinositides in cell regulation and membrane dynamics. Nature 2006, 443:651-657.
• [124]Jang JH, Lee CS, Hwang D, Ryu SH: Understanding of the roles of phospholipase D and phosphatidic acid through their binding partners. Prog Lipid Res 2012, 51:71-81.
• [125]Winkler E, Kamp F, Scheuring J, Ebke A, Fukumori A, Steiner H: Generation of Alzheimer disease-associated amyloid beta42/43 peptide by gamma-secretase can be inhibited directly by modulation of membrane thickness. J Biol Chem 2012, 287:21326-21334.
• [126]Osawa S, Funamoto S, Nobuhara M, Wada-Kakuda S, Shimojo M, Yagishita S, Ihara Y: Phosphoinositides suppress gamma-secretase in both the detergent-soluble and -insoluble states. J Biol Chem 2008, 283:19283-19292.
• [127]Rothhaar TL, Grosgen S, Haupenthal VJ, Burg VK, Hundsdorfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO: Plasmalogens inhibit APP processing by directly affecting gamma-secretase activity in Alzheimer’s disease. ScientificWorldJournal 2012, 2012:141240.
• [128]Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T: Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 2005, 7:1118-1123.
• [129]Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP: Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A 2004, 101:2070-2075.
• [130]Jana A, Pahan K: Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase: implications for Alzheimer’s disease. J Biol Chem 2004, 279:51451-51459.
• [131]Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY: Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004, 164:123-131.
• [132]Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G: Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
• [133]Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, St George-Hyslop P, Sisodia SS, De Strooper B, Heneka MT, Filippov MA, Muller U, Van Leuven F, Lutjohann D, Walter J: Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci 2008, 28:12097-12106.
• [134]Area-Gomez E, De Groof AJ, Boldogh I, Bird TD, Gibson GE, Koehler CM, Yu WH, Duff KE, Yaffe MP, Pon LA, Schon EA: Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol 2009, 175:1810-1816.
• [135]Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, De Groof AJ, Madra M, Ikenouchi J, Umeda M, Bird TD, Sturley SL, Schon EA: Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. Embo J 2012, 31:4106-4123.
• [136]Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, Park MK, Di Paolo G, Chung S, Kim TW: Presenilin mutations linked to familial Alzheimer’s disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc Natl Acad Sci U S A 2006, 103:19524-19529.
• [137]Oikawa N, Goto M, Ikeda K, Taguchi R, Yanagisawa K: The gamma-secretase inhibitor DAPT increases levels of gangliosides at neuritic terminals in differentiating PC12 cells. Neurosci Lett 2012, 525:49-53.
• [138]Pierrot N, Tyteca D, D’Auria L, Dewachter I, Gailly P, Hendrickx A, Tasiaux B, Haylani LE, Muls N, N’Kuli F, Laquerriere A, Demoulin JB, Campion D, Brion JP, Courtoy PJ, Kienlen-Campard P, Octave JN: Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol Med 2013, 5:608-625.
• [139]Girardot N, Allinquant B, Langui D, Laquerriere A, Dubois B, Hauw JJ, Duyckaerts C: Accumulation of flotillin-1 in tangle-bearing neurones of Alzheimer’s disease. Neuropathol Appl Neurobiol 2003, 29:451-461.
• [140]Gellermann GP, Appel TR, Davies P, Diekmann S: Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids. Biol Chem 2006, 387:1267-1274.
• [141]Nixon RA: Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 2007, 120:4081-4091.
• [142]Vitner EB, Platt FM, Futerman AH: Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010, 285:20423-20427.
• [143]Keilani S, Lun Y, Stevens AC, Williams HN, Sjoberg ER, Khanna R, Valenzano KJ, Checler F, Buxbaum JD, Yanagisawa K, Lockhart DJ, Wustman BA, Gandy S: Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-beta peptide. J Neurosci 2012, 32:5223-5236.
• [144]Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, Porter FD, Blennow K: Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology 2011, 76:366-372.